8.2 Duffy System
Key Takeaways
- Fya and Fyb are antithetical ACKR1 (FY) antigens; Fy3 is present on all red cells except true Duffy-nulls.
- The common African Fy(a−b−) type is an FY*B GATA-1 promoter mutation that silences Duffy on red cells only; tissues still express Fyb and P. vivax invasion is reduced.
- Anti-Fya and anti-Fyb are IgG, clinically significant, show dosage, and are destroyed by ficin and papain.
- Anti-Fy3 is made by true Duffy-nulls and still reacts with enzyme-treated Fy(a+) or Fy(b+) cells.
- Do not prophylactically issue Fyb− units to Fy(a−b−) African-American patients who have no antibody — they usually have tissue Fyb and do not make anti-Fyb.
8.2 Duffy System
Quick Answer: Fya and Fyb are antithetical antigens on ACKR1 (DARC, FY). Fy3 is a high-prevalence Duffy antigen present whenever any Duffy protein is on the red cell. The common Fy(a−b−) type in African ancestry is an FYB GATA-1 promoter mutation: red cells lack Duffy, but tissues still express Fyb, and the phenotype confers Plasmodium vivax resistance. Anti-Fya and anti-Fyb are IgG, clinically significant, show dosage, and are destroyed by ficin and papain. Anti-Fy3 is made by true nulls and still reacts with enzyme-treated cells. Do not give Fy(a−b−) African-American patients Fyb− units just because they type Fy(b−) unless the antibody is present.
Duffy is II.B.9 on the June 9, 2026 outline because candidates merge three different facts into one wrong action: the red cell types Fy(b−), so they issue Fyb− blood, so they assume the patient is a Duffy-null who will make anti-Fy3. Most African-ancestry Fy(a−b−) patients are not true nulls.
Fya, Fyb, and Fy3 on ACKR1
ACKR1 (atypical chemokine receptor 1), historically DARC or FY, lives on chromosome 1 — same chromosome as RH, different locus. The protein is a chemokine receptor that also happens to be the P. vivax / P. knowlesi red-cell invasion receptor. Fya (FY1) and Fyb (FY2) are antithetical and differ by a single amino acid (Gly42Asp, the 125G>A SNP). Fy3 is an epitope on the Duffy protein that is present on Fy(a+) and Fy(b+) cells and absent only when the protein itself is missing from the membrane.
Classic teaching phenotypes:
| Phenotype | European ancestry | African ancestry | What the red cell carries |
|---|---|---|---|
| Fy(a+b−) | ~17% | ~9% | Fya and Fy3 |
| Fy(a+b+) | ~49% | ~1% | Fya, Fyb, and Fy3 |
| Fy(a−b+) | ~34% | ~22% | Fyb and Fy3 |
| Fy(a−b−) | Rare | ~68% | No Fya, Fyb, or Fy3 on the RBC |
Fya is more immunogenic than Fyb, so anti-Fya is the Duffy antibody you identify most often. Both antibodies are IgG, 37 °C / AHG, clinically significant, and capable of HTR and HDFN. They show dosage: a heterozygous Fy(a+b+) cell can look weak or negative while a Fy(a+b−) cell is 2+ or 3+. Always include a double-dose (homozygous) cell before you rule Duffy out.
Ficin and papain destroy Fya and Fyb. A panel that goes silent after enzyme treatment is consistent with Duffy or MNS (M/N, sometimes S/s), not with Kidd, Rh, or Kell. That enzyme pattern is half of the identification. The other half is the GATA story below.
The GATA-1 promoter mutation is not a deleted gene
The common African Fy(a−b−) red-cell type is FYB with a GATA-1 binding-site mutation in the erythroid promoter (classically taught as −67T>C). GATA-1 cannot dock, so ACKR1 is not transcribed in the red-cell lineage. Endothelium and other tissues use a different promoter, so Fyb is still made in tissues. A microarray that reads only the 125G>A Fya/Fyb SNP will call the person Fyb+ while the red cells type Fy(b−). That genotype–phenotype mismatch was already the teaching example in Section 5.1. It is not a broken chip.
Three clinical payoffs sit on that single mutation:
- Malaria. Plasmodium vivax (and P. knowlesi) needs Duffy to invade the red cell. Fy(a−b−) red cells are resistant to P. vivax. This is not the main P. falciparum receptor story — do not swap the species on a BB item.
- Anti-Fyb is unusual. The patient still sees Fyb in tissues, so the immune system is not looking at a foreign antigen. Anti-Fya can still form if the person is exposed to Fya+ red cells, because they never made Fya. Anti-Fy3 is also unusual in GATA-silenced patients, because they are not missing Duffy protein everywhere.
- Do not prophylactically phenotype-match Fyb. A Fy(a−b−) African-American patient with a negative antibody screen does not automatically need Fy(a−b−) or Fyb− units. Issue units that match any identified antibody (often anti-Fya, or an unrelated antibody). Honoring a Fy(b−) type that is only a red-cell silence wastes antigen-negative inventory.
True Duffy-nulls are different. Rare inactivating ACKR1 mutations abolish the protein in all tissues. Those people can make anti-Fy3 (and sometimes anti-Fya, anti-Fyb, or anti-Fy5). Anti-Fy3 reacts with all cells except Fy(a−b−) and, critically, still reacts after ficin or papain because the Fy3 epitope is enzyme-resistant. That is how you separate anti-Fy3 from anti-Fya or anti-Fyb on an enzyme panel: Fya/Fyb disappear; Fy3 does not.
Fy^x is a weak Fyb that some reagents miss. The patient may type Fy(b−) with one clone and Fy(b+w) with another. Molecular typing or a different anti-Fyb clone prevents you from calling every weak Fyb a GATA silence.
Antibody identification and unit selection
Work a suspected Duffy antibody the way the bench actually works it:
- Reactivity at AHG, stronger with Fy(a+b−) or Fy(a−b+) double-dose cells than with Fy(a+b+) cells (dosage).
- Destroyed by ficin/papain if the specificity is anti-Fya or anti-Fyb.
- Not destroyed by DTT — Duffy is not Kell.
- If the serum still reacts with enzyme-treated Fy(a+) or Fy(b+) cells and is silent only with Fy(a−b−) cells, stop calling it anti-Fya and start calling it anti-Fy3.
- Once identified, honor anti-Fya and anti-Fyb for every red-cell transfusion. They are not Lewis. They are not room-temperature anti-M.
What you should not do is look at an African-American type-and-screen that reads Fy(a−b−), invent anti-Fyb that is not there, and deplete the Fy(b−) stock. Section 5.3 already ranked immunogenicity; this section ranks what the patient can actually make. GATA-silenced FY*B patients make anti-Fya far more often than anti-Fyb. Wait for the antibody.
If a chronically transfused sickle-cell patient of African ancestry needs extended matching, match C, E, K, and other demonstrated antibodies first. Adding prophylactic Fyb matching for a GATA Fy(a−b−) type is not the default BB rule unless a local SCD protocol says otherwise and the antibody history supports it.
Exam traps
- Treating every Fy(a−b−) African-American patient as a true null who will make anti-Fy3.
- Issuing Fyb− units solely because the red cells type Fy(b−).
- Naming P. falciparum as the Duffy-receptor malaria. The BB pairing is P. vivax.
- Expecting enzymes to destroy anti-Fy3. Fy3 is enzyme-resistant; Fya and Fyb are not.
- Ruling out anti-Fya on a single Fy(a+b+) heterozygous cell. Dosage will fool you.
- Using DTT to strip Duffy. DTT is the Kell reagent, not the Duffy reagent.
- Believing a Fyb+ microarray result contradicts Fy(a−b−) red cells — that is the GATA-1 signature, not a labeling error.
A patient of African ancestry types Fy(a−b−). Which statement is the correct BB interpretation of the common mechanism?
Anti-Fy3 is identified in a true Duffy-null donor. What happens when the panel is repeated with ficin-treated cells?
An African-American patient types Fy(a−b−). The antibody screen is negative and there is no historical Duffy antibody. What is the appropriate red-cell selection?